219 related articles for article (PubMed ID: 9566916)
1. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK
Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
LaMontagne KR; Hannon G; Tonks NK
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14094-9. PubMed ID: 9826659
[TBL] [Abstract][Full Text] [Related]
3. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
5. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.
Harrison-Findik D; Susa M; Varticovski L
Oncogene; 1995 Apr; 10(7):1385-91. PubMed ID: 7537361
[TBL] [Abstract][Full Text] [Related]
6. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
7. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase.
Fukada T; Tonks NK
J Biol Chem; 2001 Jul; 276(27):25512-9. PubMed ID: 11316810
[TBL] [Abstract][Full Text] [Related]
8. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
9. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
[TBL] [Abstract][Full Text] [Related]
10. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
Pendergast AM; Gishizky ML; Havlik MH; Witte ON
Mol Cell Biol; 1993 Mar; 13(3):1728-36. PubMed ID: 8441409
[TBL] [Abstract][Full Text] [Related]
11. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
12. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
Wertheim JA; Forsythe K; Druker BJ; Hammer D; Boettiger D; Pear WS
Blood; 2002 Jun; 99(11):4122-30. PubMed ID: 12010816
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
15. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
[TBL] [Abstract][Full Text] [Related]
17. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.
Alvira D; Naughton R; Bhatt L; Tedesco S; Landry WD; Cotter TG
J Biol Chem; 2011 Sep; 286(37):32313-23. PubMed ID: 21795709
[TBL] [Abstract][Full Text] [Related]
19. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.
Di Cristofano A; Carpino N; Dunant N; Friedland G; Kobayashi R; Strife A; Wisniewski D; Clarkson B; Pandolfi PP; Resh MD
J Biol Chem; 1998 Feb; 273(9):4827-30. PubMed ID: 9478921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]